Targeting Fibroblast Growth Factor Receptors in Preclinical Patient-Derived Xenograft Models of CRPC

ABSTRACT

In this reporting period, the didactic coursework and training opportunities that were proposed for this project were completed. However, significant disruptions to research activities were encountered due to the ongoing COVID-19 pandemic response and ACURO approval delays. These factors led to the application and approval of a no cost extension to complete all proposed work. Nevertheless, all study approvals (IACUC, ACURO, HRPO) have been obtained and experiments using fibroblast growth factor receptor and androgen receptor inhibitors inpatient derived xenograft models are underway. The approved project objectives and scope will not change and the work to be completed in the extension period will include all experiments and analyses related to Specific Aim 1.